8010 222 777


Aroma Seatone (Biolane GLME)

About Seatone

Aroma Seatone GLME® (Biolane Extract) is made from extract of Green Lipped Mussel (GLM), an edible shellfish found off the coast of New Zealand. Since its discovery in 1974, Seatone GLME has been subjected to more than forty years of quality scientific research and the joint health benefits have been shown in laboratory and clinical trials. It is found to be beneficial in both osteoarthritis and rheumatoid arthritis. It aids in the recovery of injuries or surgery to joints.

Seatone GLME contains anti-inflammatory agents, immune modulators and many essential building blocks – all naturally occurring substantial therapeutic agents known to maintain joint mobility & wellbeing.

It is known to provide relief from pain, protecting cartilage, repairing joints, reducing the inflammation and improving general mobility. It usually provides relief which may be gradual, progressive and normally long-term. The first thing to be noticed is a reduction in pain, which is then followed by gradual improvement in grip strength, freedom of movement or other mobility. Most people see visible improvement after 4-8 weeks of starting Seatone GLME, but it can take up to 3 months.

GLM is widely consumed by the local population of New Zealand and is classified as a ′basic food status′ product. No adverse effects have been reported with long-term use even at high levels of consumption. Toxicity studies at Auckland Hospital were unable to find toxic level of Seatone GLME at 120 times the standard dosage.

Seatone® is a trusted brand from more than 40 years and is sold in over 30 countries.

Advisory: This is not intended for the diagnosis or treatment of medical complaints. It is for information purposes only.

New Zealand Green Lipped Mussel Extract

Green lipped mussel is a shellfish which is native of New Zealand. It gets it′s name due to the green lip surrounding the edge of its shell. They may grow up to 240 mm in length, making them one of the largest mussel species. They are grown in pristine coastal waters of New Zealand. To maintain the quality of mussels, seawater in the farms is tested for bacteria, Biotoxins and heavy metals. The water quality is tested out according to the standards set by the European Union, U.S Food and Drug Administration, and NZ Food Safety Authority.

It was found in 1974 that the green lipped mussel is a potential natural remedy for arthritis. Thus it is available commercially as a food supplement from 1974. It is found to be effective in the treatment of both rheumatoid arthritis and osteoarthritis after laboratory and clinical trials which were done on both human and animal subjects. It works by anti-inflammatory activities. It blocks the migration of neutrophils (soldier cells) from the blood vessels thus it inhibits them from attacking our own cells in conditions when an inflammatory spur is present. Thus it helps to reduce the pain and increases mobility. It owns a property of being gastro-protective thus it does not damage the soft lining of stomach and also protects the stomach lining from the harsh effects of the some of the pain killers that a person takes during the conditions of arthritis.

Advisory: This is not intended for the diagnosis or treatment of medical complaints. It is for information purposes only.

Seatone for Arthritis

Arthritis is a joint disorder, which can even make a person crippled. The condition of arthritis makes a person feel helpless and unhappy with life. Patients with arthritis generally become frustrated with their life as they are unable to get relief even after long periods of treatment. This happens because the treatments available for arthritis usually provide temporary relief and show a number of side effects.

Seatone is a dietary supplement, which provides long-lasting relief without causing side effects. it is obtained from the extract of Green Lipped Mussel (GLM) which is an edible shellfish found in New Zealand. Its joint health benefits have been demonstrated in laboratory and clinical trials. It contains naturally occurring therapeutic agents which are known to maintain joint mobility and well being. It has immune modulators, anti-inflammatory agents and many essential building blocks.

Seatone provides relief from a gradual improvement in grip strength, mobility and freedom of movement. Thus, it shows a great benefit in the treatment and management of arthritis. Most of the arthritis patients observe improvement after 4-8 weeks of Seatone use. However, in case of some people, it may take up to 3 months. Generally, the improvement with Seatone is slow but progressive. Firstly, it shows a reduction in pain and then with time it improves the joint mobility.

Role of Seatone in the treatment of Arthritis

Seatone prevents the joint deterioration and repairs the cartilages that are deteriorated due to the condition of arthritis. It lubricates the joints and enhances the joint mobility. It controls the inflammation and decreases the swelling and, which is due to joint damage. It acts as gastro-protective and also aids other medicines to show their maximum efficacy in the treatment of arthritis.

Seatone being obtained from a natural source does not show any side effects; even it protects the stomach lining from the adverse effects of other medicines that are used in the treatment of arthritis.

Advisory: This is not intended for the diagnosis or treatment of medical complaints. It is for information purposes only.

Dosage & Expectations

An adult patient of arthritis should take 1000mg (2 capsules) daily for 6-12 weeks; 500mg (1 capsule) daily for maintainence thereafter. For best results, Seatone should be taken along with meals.There is no limit for long term use. Most people experience a benefit in 4-8 weeks after starting Seatone. First effect could be experienced within 2-3 weeks but may take as long as 3 months, few people may experience increased tenderness & heat around afflicted joints after a few days usually an indicator that the product is working on the joints. Any benefit to joints is gradual, progressive and normally long term. Thus, it is important to stay on the program till relief from symptoms is experienced.

Advisory: This is not intended for the diagnosis or treatment of medical complaints. It is for information purposes only.


  • Individuals with shellfish allergy or gout are advised not to use Seatone.
  • It is also suggested that Seatone should not to be used by persons using prescription blood thinners or monoamine oxidase inhibitory drugs.
  • People on a completely salt-free diet may also want to avoid using Seatone because it contains natural minerals and very small amounts of natural sea salts.
  • Not recommended during pregnancy or breastfeeding. Keep out of reach of Children.

Advisory: This is not intended for the diagnosis or treatment of medical complaints. It is for information purposes only.

New Zealand Green Lipped Mussel Vs NSAID

NSAIDs (Non-steroidal anti-inflammatory drugs) are the drugs which are commonly used to get relief from pain, reduce fever or reduce inflammation in different conditions including arthritis. There are some strong NSAIDs also that can improve your condition immediately but they show severe side effects. It is true that NSAIDs provide rapid action but it is also true that they only provide temporary relief. While the GLM provides you long lasting effects even if its action is slow.

NSAIDs can damage your cartilage, can arouse stomach ulceration, and can cause renal dysfunction or hemorrhage. It may also dilute your blood by influencing the platelets, may increase your blood pressure, can increase the chances of heart attacks, and can stimulate the skin problems. While the GLM extract aids you to regenerate and recover the cartilage. It is gastro-protective and do not effect adversely to platelets or renal function. It does not aggravate your blood pressure nor does it cause the risk of heart attacks. It may help you to treat the condition of psoriasis. Therefore you can easily find that NSAIDS can show serious adverse effects while the GLM extract is quite safe.

Advisory: This is not intended for the diagnosis or treatment of medical complaints. It is for information purposes only.

Seatone Vs Other Mussel Extracts

Why choose Seatone over other Green Lipped Mussel extracts?

Early research on green-lipped mussels showed that simply drying and encapsulating mussels did not produce a consistent product. Additionally, non-active components of the mussels diluted the activity. Aroma uses two processes to overcome this problem:

  • A new processing method of cold extraction remove the fresh mussel from the shell and quickly extract and stabilise the active component; and,
  • freeze-drying to preserve and stabilise the product.

This process ensures there is a huge difference between Seatone GLME and other products marketed as GLME which are actually little more than ground up frozen or even frozen and cooked mussel powder. This kind of processing minimises and can even destroy the potency of the product. This can be proven by a special laboratory test specifically developed by Aroma for proving that each production batch of GLME has an acceptable level of activity. There are some other mussel products currently being marketed as an extract, which is only the lipids (oils and fats) portion of the mussel which has been extracted through the use of a solvent. While Seatone is much effective because it is the whole extract of GLM.

Raw Material

Seatone is unique from other GLME as it is extracted only from the premium, fresh mussels when they are in peak condition only with the intention of producing a therapeutic product for joints.


The Company keeps full control of the practice, to make sure that harvesting is done at the best times of each year. Other companies do not take this much control so they use mussels of the food-industry grade. Therefore they harvest the mussels year round rather than harvesting them at their peak condition.

Most importantly, most of the clinical researches have been carried out on Seatone GLME which is produced only in New Zealand by Aroma NZ Ltd.in a process which ensures the potency and consistency of the product.

Advisory: This is not intended for the diagnosis or treatment of medical complaints. It is for information purposes only.

Nutritional Content

Seatone is an excellent source of essential nutrients. It contains naturally occurring mucopolysaccharides, Omega 3, proteins and minerals.

Prepared from marine mussels, the extract has naturally assimilated micronutrients from its sea environment, in a manner, which retains all the components in a stable and functional state.

Seatone® Green Lipped Mussel Extract Typical Nutritional Information

Nutritional Table

General Components Result Vitamin Components Result
Protein 56.8% Vitamin A 131.5 IU/100g
Omega 3 Fatty Acids 4.5% Vitamin D3 1640 IU/100g
Fat 10.8% Vitamin E 2.8 IU/100g
Moisture 2% Amino Acid Components Result
Ash 18.1% Aspartic Acid 42.8 mg/g
Carbohydrate 12.4% Glutamic Acid 58.8 mg/g
Energy 1570 kJ/100g Serine 18.9 mg/g
Saturated Fat 3.3% Histadinee 8.5 mg/g
Mineral Components Result Glycine 43.8 mg/g
Copper 5.6 ppm Threonine 21.2 mg/g
Zinc 57 ppm Arginine 35.9 mg/g
Manganese 15 ppm Alanine 24.5 mg/g
Boron 28 ppm Valine 14.6 mg/g
Chromium 1.4 ppm Methionine 9.5 mg/g
Iron 380 ppm Phenylalanine 14.8 mg/g
Calcium 15000 ppm Isoleucine 17.7 mg/g
Phosphorus 12500 ppm Lysine 51.3 mg/g
Sodium 36000 ppm Leucine 17.9 mg/g
Potassium 12000 ppm L Cystine 664.5 mg/100g
Magnesium 4900 ppm Proline 19.7 mg/g
Nickel 1.3 ppm L Cystine 664.5 mg/100g
Sulphur 12000 ppm Tyrosine 15.4 mg/g
Potassium 39000 ppm Tryptophan 5.2 mg/g

Seatone® is a naturally occurring compound and the above information is a typical analysis. As with any natural product, variations can occur.

Does not contain: wheat, gluten, milk derivatives, yeast, sugar, corn, starch, colour, flavour or preservatives.

Advisory: This is not intended for the diagnosis or treatment of medical complaints. It is for information purposes only.

Is Seatone Safe?

Extensive studies on toxicity have been carried out on Aroma Seatone and no toxic effects were observable in the test subjects at 120 times the standard dose.

These studies are similar in design to those conducted by pharmaceutical companies to show that a drug is safe to use in people. Not only was Seatone GLME safe at very high dosages, but it also had no teratogenic effects. Aroma Seatone GLME was first introduced to the New Zealand market in April 1974. Since that time the demand for this product has spread to over 30 countries worldwide. Although the product is derived from a shellfish, which is extensively consumed as food, it has been subjected to both toxicity and teratogenic trials to ensure that the derived material is as safe to consume as the original food source.

It is pertinent to comment that a significant amount of this product has been consumed by human subjects under the strict supervision of clinicians during clinical studies carried out in New Zealand, Australia, United Kingdom, and France.

Source of Raw Material – Green Lipped Mussels

Shellfish used to produce Aroma Seatone GLME are from cultivated sources (marine farms) and the farms are licensed by the New Zealand Government. The fact that the farms are licensed ensures that they are located in suitable (unpolluted) areas of the coastal waters and also that shellfish may only be harvested from them when conditions are appropriate.


Government has established a Biotoxins Management Committee to monitor areas of the coastal waters where farming of shellfish takes place. Regular sampling of the phytoplankton is done which is present in water to ensure that algal species with Biotoxins are not much in numbers to cause toxicity. Moreover the samples of mussels are sent to laboratories to detect the presence of Biotoxins

Microbiological Contaminants

Because marine farming is essentially a coastal water operation, it is subject to the influence of land drainage and other discharges, which have the potential to cause microbiological contamination of the waters. Mussels are filter-feeding animals and thus are able to concentrate contaminants as well as foods from their surrounding waters. Although the licensing criteria for marine farms require that they be situated away from areas directly influenced by sewage and other such discharges there is always the possibility of microbiological contaminants from sea birds, run off waters from grazing pastures etc being present in the waters of the farm area.

To prevent any risk of microbiological contaminants being present in cultivated mussels, or the extract processed from them, routine monitoring of the waters is carried out and, in addition, every batch of mussels received for processing is subjected to microbiological assays at the factory on arrival. Further, the factory quality control programme requires that the processing of the mussels, through the several stages from shellfish to powder or capsules, be monitored by sampling and analysis for microbial levels by the in house laboratory.

As a final safeguard, the end product in powder or capsule form is subjected to microbiological assay and certification by an independent, Government approved laboratory.

Heavy Metal Contaminants

most countries to which the mussel extract product is exported have mandatory maximum levels for the content of heavy metal contaminants in food products they will accept. New Zealand is not an industrialized nation thus there is not a huge extend of metal contaminants that can cause issues in marine derived products. However the samples of the final product are sent for analysis to government approved laboratories to certify it.

Pesticides and Herbicides

The herbicide and pesticide residue testing is done on mussels and on random batches of final mussel extract to attain the full safety of a product.

Safety Aspects during Manufacture

The manufacturing process for Aroma Seatone GLME is carried out to a Hazard Analysis Critical Control Point (HACCP) programme as required by the USFDA for products acceptable to the USA. The programme has been approved by the Regulatory Authority (MAF) appointed by the USFDA for local administration under a Memorandum of Understanding between the two countries. The Company has an HACCP Coordinator on staff and the requirements of the programme ensure that reception of shellfish and subsequent manufacture is all carried out to the approved standards. In addition the Company has its own laboratory and quality assurance and control programme which monitors the reception of raw materials and their progress through the processing stages.

Pharmacological Safety of the Product

As mentioned above, Seatone GLME has been subjected to both toxicity and teratogenic studies by the Department of Medicine at the University of Auckland. Although the Green Lipped Mussel Extract is a food these studies were conducted to the standard protocol as used for new drug products since they apply equally to food or drugs. The product has been shown to be nontoxic and not teratogenic.


Aroma Seatone GLME processed in the manner and to the standards described above is a safe product for consumption on a continuous and regular basis.

Advisory: This is not intended for the diagnosis or treatment of medical complaints. It is for information purposes only.

Raw Material

New Zealand Green Lipped Mussel Extract (GLME) is the anti-inflammatory agent in Aroma Seatone. The Green-lipped mussels are farmed in several parts of New Zealand, but mussels for Seatone GLME are obtained almost exclusively from the Coromandel Coast. This isolated peninsula, east of Auckland, produces some of the highest-grade green-lipped mussels in New Zealand.

Both, the water and shellfish quality are regularly monitored in government laboratories. In addition to this, the laboratories carry out further microbiological and physical testing to ensure that the final product meets the highest international standards.

Advisory: This is not intended for the diagnosis or treatment of medical complaints. It is for information purposes only.


Early research indicated that simply drying and encapsulating green-lipped mussels did not produce a consistent product. Additionally, non-active components of the mussels diluted the activity.

Two processes were combined to overcome this problem:

  • First, a new and innovative Cold Extraction method was designed which both extracted the mussel from the shell and quickly extracted the active fraction.
  • Second, freeze-drying was used as the means of preserving and stabilizing the product.

It is important to note that Seatone GLME is the only green-lipped mussel extract to be manufactured using this unique activity-conserving process.

Aroma has invested over 35 years of research into the production and effectiveness of Seatone GLME. As the green-lipped mussels reach peak condition at 18 months of age, they are harvested and shipped live in refrigerated trucks to Aroma factory. The mussels are transferred to cool storage and processed through a unique cold extraction process, which is completely natural, avoiding the use of solvents. This results in a highly active freeze dried extract of green-lipped mussels – Seatone. This extract is milled to produce a fine powder and encapsulated in hard gelatin Seatone capsules.

Advisory: This is not intended for the diagnosis or treatment of medical complaints. It is for information purposes only.

Cinical Research

Cheras PA. Vascular Mechanisms in Osteo-arthritis: Rationale for Treatment with a Marine-Based Complementary Medicine, Osteo-arthritis and Cartilage 2005, Volume 13, page S95.

Cheras PA, Stevenson L, Myers SP. In-vitro Biological Activities of Biolane: A comparative study. ACCMER (Australia), Sep 2005

Study Aim

In vitro laboratory studies were undertaken by the Australian Centre for Complementary Medicine Education and Research (ACCMER), a joint venture of the University of Queensland and Southern Cross University. The aim of the studies was to compare selected biological activities of Healtheries′ Biolaneâ„¢ Green Lipped Mussel Extract versus the biological activities in a range of well known complementary anti-arthritic agents.

Sample Preparation

All samples were subjected to two enzyme digestions to simulate in vivo digestive processes. Various components of gastrointestinal secretions may have an impact on potential actives within a product. In this study we used a two stage in vitro model based on gastric and duodenal secretions. The digests prepared from the samples were a pepsin digest containing the prominent gastric enzyme pepsin and a complete digest where the sample was exposed to pepsin followed by pancreatic enzymes.


Assays assessed:
  • cholesterol synthesis inhibition
  • anti oxidant capacity
Inhibition of the following components of inflammatory pathways
  • tissue necrosis factor alpha (a)
  • Cox-2 expression
  • prostaglandin E2 (PGE2)
  • phospholipase A2 (PLA 2) – also associated with platelet aggregabillity
  • platelet aggregation inhibitory activity
  • fibrinolytic activity

Synopsis of Results

Comparison of aggregate in vitro data – Chondroitin Sulphate (CS) vs Glucosamine Sulphate (GS) vs Glucosamine sulphate:Chondroitin sulphate (GS/CS) vs LyprinolT vs Healtheries Biolaneâ„¢ Green Lipped Mussell Extract (GLME)

Test Anti-arthritic agent
Cholesterol biosynthesis inhibition
TNFa inhibition
Cox-2 inhibition ND
PGE2 inhibition
PLA2 inhibition *
Oxygen radical absorbance capacity – antioxidant (ORAC)
Fibrinolytic activity
Anti-platelet aggregation activity
Note denotes activity present denotes activity not found

* denotes activity not found at low concentration but present at higher concentration

ND = not done (test unable to be performed due to assay artefact)

The results show that Healtheries Biolaneâ„¢ Green Lipped Mussel Extract (GLME) demonstrates the most comprehensive range of activities across the suite of in vitro tests performed when compared with the other agents that were tested.

Relevance of the in vitro BiolaneT green lipped mussel extract (GLME) findings to putative Osteoarthritis pathomechanisms

The vascular theory of osteoarthritis causation is based on epidemiological, laboratory, experimental and clinical findings that support the concept that compromised microcirculation in affected joints initiated through a combination of inflammation and imbalance between coagulation and fibrinolysis can initiate and perpetuate the disease. One implication of this theory is that in order to treat more than just painful symptoms ie to slow or halt the disease process will require a range of biochemical activities to effectively break the web of pathology. It has been proposed that these should include a number of key activities such as anti-inflammatory, anticoagulant, fibrinolytic and lipolytic activities. If these are realised then chondroprotection is likely to ensue.

The use of highly potent anti-inflammatory agents, particularly the Cox-2 inhibitors would appear to be at odds with the known data showing that patients with osteoarthritis are at greater risk of thrombotic episodes than those without the disease. Cox-2 inhibitors pose a theoretical risk of increased thrombotic complications in many patients with osteoarthritis who already have cardiovascular risk factors. The recent removal of Vioxx from the market and restrictions governing the use of Celebrex – the Cox-2 market leaders, based on these concerns would appear to support this proposition.

A successful anti-arthritic agent should have multiple low level activities that address a range of disease drivers while avoiding the serious side effects that frequently accompany massive disruption of major biochemical pathways such as total Cox-2 inhibition.

The current in vitro study has shown that GLME has a range of activities that the vascular theory of osteoarthritis causation predicts as desirable for disease treatment. These include anti-inflammatory activity through its inhibition of TNFa, PGE2, Cox-2 and PLA2 in addition to its anti-oxidant activity. It is not critical for these activities to be at extremely high levels. In fact it is advantageous from the perspective of a low side effect profile that they should not be so. It is the multiplicity of activities that is of greater importance. In addition to anti-inflammatory activity, GLME also has in vitro activities that can reduce thrombotic risk (decreased PLA2 and cholesterol biosynthesis inhibition activity in addition to decreased platelet aggregability – that is also assisted through cholesterol biosynthesis inhibition) and enhance the removal of blood clots (mild fibrinolytic activity).

The results obtained in this study indicate that GLME has in vitro activities in key areas associated with arthritis pathophysiology. In addition, across the range of in vitro tests performed in this comparative study, Healtheries BiolaneT green lipped mussel extract demonstrated a more extensive range of potential anti-arthritic activities in comparison to the other agents tested.

It is important to note that these results apply specifically to BiolaneT Green Lipped Mussel Extract and can not be extrapolated to include other green lipped mussel extracts.

Advisory: This is not intended for the diagnosis or treatment of medical complaints. It is for information purposes only.

Kendall RV, Lawson JW, Hurley LA. New research and a clinical report on the use of Perna canaliculus (Biolane) in the management of arthritis. Townsend Letter for Doctors and Patients, July 2000; 99-111


This paper includes the results of a laboratory research into the mechanisms of action of the mussel extract and also those from a 4-year clinical study involving 120 patients suffering osteo arthritis. The results, which originate from a university and also a clinical practice in the USA are once again excellent and fully support all the earlier positive data for the product.

Sixty-four males and fifty-six females made up this group with most patients in the age group of 60-70. Several of them had been referred total knee replacement. All patients in the study were provided information on the use of Green Lipped Mussel (GLM) for degenerative joint disease. They were advised that GLM Extract had been shown to have an anti-inflammatory effect equal to that of Indocin but more importantly it had a nutritive metabolic effect. The importance of mucopolysacharrides (glycosaminoglycans) in the formation of basic proteoglycans cartilage was stressed.

Patients with a known allergy to seafood, shellfish and alfalfa were excluded from the study but patients who were taking some form of NSAIDs or pain medication were allowed to continue but were requested to keep a record of all medications required.

Pain Assessment

The Huskinson visual analogue pain scale was used to assess pain where the pain intensity ranged from ” no pain” to “worst possible pain “. (Intensity Scale Fig. 1.)

Inflammatory Index

An estimate of overall inflammatory activity of the joints based upon clinical evidence of swelling, trauma, redness, heat and pain was made. A history of ” minutes of morning stiffness” as well as daily activity, participation in sports etc. was recorded by the patients.

The patient′s opinion of their condition in comparison to their initial state (same, a little better, a lot better, worse, much worse) was recorded. The physician′s evaluation was also made at the time of each visit (excellent, good, no change).

Notes were made as to tolerance of GLM Extract and compliance. Notes were also made in reference to the use of NSAID′s, pain medication, tropical cream and ointments.

The patients were prescribed 3 GLM Extract capsules (a total of 1500mg extract) per day taken with food and then 2 capsules daily as a permanent maintenance dose. The product used in the study contained 500mg GLM and 100mg alfalfa. The study was designed to last one year and out of 120 patients, only eleven were eventually elected for total knee replacement.

X-RAY evaluation

X-Rays of the patients were graded on the basis of a scale of I to IV using the Kellgren and Lawrence system – degree of osteoarthritis progressing by grade from grade I (minimal, least, severe) to grade IV (bone on bone).

The response to management in these groups of patients studied became evident at the time of the first follow-up visit. Many grade I & II patients who had presented with an initial analogue of 7 reported a 0 – 2. These patients continued to remain comfortable and active during the rest of the study.

Evidence of pain, heat and swelling was noted to be significantly diminished or absent during the remaining visits.

The two patients who were using canes no longer required them. A significant number of patients were able to reduce their NSAID intake by 50% or more. Most patients reported that their condition was much improved. No patient complained that his condition was worse.

Patient′s and Practitioner′s Assessments

95 patients reported of much improvement and 16 reported of some improvement. 9 patients reported of no change.

According to the practitioner, 19 patients (27%) had shown no improvement, 38 patients (31%) had shown good improvement and 63 patients (52%) had made excellent progress.

11 patients did eventually come for joint replacement therapy but felt that GLM protocol had bought them some more time.

Advisory: This is not intended for the diagnosis or treatment of medical complaints. It is for information purposes only.

Lambert M, Semark A, Grobler L. The ergogenic properties of Seatone (Biolane). Research Report by MRC/UCT Bioenergetics of Exercise Research Unit, UCT Medical School, Sport Science Institute of South Africa, 31st August 1998

In this study, conducted at the UCT Medical School in South Africa, the effects of Biolane GLME on recovery from muscle injury were compared with those of placebo in 20 highly trained athletes (cyclists). The cyclists took Biolane GLME for 3 weeks before muscle injury was induced. Peak power was greater and recovery of peak power faster in the group who were taking Biolane GLME than in those taking placebo. This is the first study to suggest that Biolane GLME can aid in the recovery of soft tissue injury in healthy individuals.

Advisory: This is not intended for the diagnosis or treatment of medical complaints. It is for information purposes only.

Audeval, B, Bouchacourt, P. Double blind, placebo-controlled study of the mussel Perna canaliculus (Biolane) in gonarthrosis (arthritis of the knee).
La Gazette Medicale 1986; 93 (38):111-115


This double blind clinical study was conducted to the full European protocol as detailed in the European Directive on clinical trials of New Drugs Against Rheumatism. It was a very well conducted trial, involving 53 carefully matched patients over a period of six months. The trial was conducted at two Rheumatology centers in Paris and produced positive results indicating the effectiveness of the mussel extract for this condition.

The patient′s conditions were confirmed by a radiographic analysis and they had clinically experienced a steady pain for several weeks. The study lasted 6 months using 6 capsules (2100mg of GLM Extract per day) versus a matched placebo.

Ten efficacy measures were employed and patients were examined monthly. Results showed that the GLM Extract group was statistically superior to the placebo group in 4 of the 10 test areas:

  • Pain and discomfort
  • Functional index ARA
  • Patient′s opinion on results of treatment
  • Treatment effectiveness judged by the doctor

The placebo group showed a greater reduction in ′morning stiffness′ as compared to the GLM extract group.


The results were also influenced by the severity of the illness. GLM Extract appeared to be more effective in less serious and moderate cases and not as effective in the more advanced stages.

The researchers concluded that GLM was effective by influencing the evolution of the arthritic illness – stopping the deterioration and enhancing the repair mechanism rather than by just working as an analgesic or purely as symptomatic anti-inflammatory agent.

Advisory: This is not intended for the diagnosis or treatment of medical complaints. It is for information purposes only.

Audeval, B, Bouchacourt, P. Double blind, placebo-controlled study of the mussel Perna canaliculus (Biolane) in gonarthrosis (arthritis of the knee).

La Gazette Medicale 1986; 93 (38):111-115

The study was conducted in two phases using four groups of five male and female Fischer rats.

Phase one involved monitoring the response of the rats to a single high dose (8g per kg bodyweight) of Seatone. No signs of toxicity were found and all amimals were alive and healthy 2 weeks after administration of the Seatone.

In phase two the rats were fed Seatone at a daily dose of 2g per kg bodyweight per day administered orally for 14 day. No signs of toxicity were found.

The animals were examined daily over a period of fourteen days. At the end of fourteen days the animals were euthanized and a post mortem conducted with heart, lungs, stomach and intestines being examined. Blood samples were also taken from the animals involved in the phase two experiment for determination of haematological parameters.

After two weeks all animals in both phases of the experiments were alive and healthy and it was found that Seatone did not exhibit acute toxicity. Due to the absence of toxic effects it was not possible to establish the LD50 for Seatone and the author concluded that the experiments demonstrated the Seatone does not exhibit acute toxicity when tested in rats.

In body weight terms of a 70 kg human, this would be equivalent to 120 gram per day. The recommended human dose in humans is 1 -1.2 gram per day.

FOOTNOTE: Long Term Toxicity.
The absence of toxic effects due to daily ingestion of Seatone over the long term has since been demonstrated by the fact that the product has been subjected to a number of clinical studies of duration up to six months in human subjects with no incidence of adverse events. In addition, widespread international use of the product by humans for more than 30 years has not resulted in any reports of toxic events.

Advisory: This is not intended for the diagnosis or treatment of medical complaints. It is for information purposes only.

Authors: TE Miller, HWu.

Dept of Medicine, University of Auckland, New Zealand. May 1981

The study monitored the teratogenic effects of Seatone using 20 breeding pairs of Dark Agouti rats for each of the test and control groups over a period of 6 months. The rats were fed either a standard diet or the diet containing Seatone for 90 days prior to mating.

The control animals were fed powdered pellets of a standard diet, and active group animals were fed Seatone blended in to a formulation that was estimated to equate to 50 time the recommended dosage for humans. Subsenquent analysis indicated that the formulation represented 54 times the recommended human dosage.

Autopsies were carried out on progeny from both groups at 21 days of age, test group, control group with rats from both groups also being processed for histological examination. Additionally, examination of near term (20 days) foetuses from the second litters of both groups, were examined for skeletal abnormalities and malformations.

No teratogenic effects were observed at the doses consumed (54 times normal)

The litter sizes in the Seatone fed group were significantly smaller although the average weight of the Seatone progeny was greater at both 4 and 21 days.

The study concluded that Seatone delayed conception. There were no skeletal abnormalities or malformations in either group but delayed skeletal development was observed in a greater number of animals in the Seatone group to those in the control group.

Advisory: This is not intended for the diagnosis or treatment of medical complaints. It is for information purposes only.

Gibson RG, Gibson SL, Conway V, Chappell D. Perna Canaliculus (Biolane) in the treatment of arthritis.
The Practitioner September 1980, 955-960


This was the first long term double blind clinical study to be conducted on the mussel extract and it produced very exciting results. The results indicated that the product was not only successful in treating the rheumatoid forms of arthritis but also osteo arthritis.

In a preliminary test carried out with 86 patients, 55 had rheumatoid arthritis and 31 had osteo arthritis. The trial results indicated that 67.9% of the rheumatoid patients and 39.5% of the osteo patients benefited from GLM supplementation . An interesting point relating to these figures is that they agreed with those compiled from unsolicited anecdotal reports originating from people in countries all around the world.

This was followed by a double blind, placebo controlled study involving an additional 66 patients. Of these, 28 had rheumatoid and 38 had clinical and radiological evidence of osteo arthritis. All patients were taking some form of NSAIDs.

Clinical assessments like the ones mentioned below were monitored before and after a 3-month trial period where the test group received 1050mg of GLM extract per day and the control group received the placebo:

  • Joint mobility
  • Pain index
  • Swelling
  • Function tests
  • Laboratory indices


Results of the study, after removing eight patients who dropped out due to unrelated reasons, were as follows: 76% of the rheumatoid and 45% of the osteo arthritis group reported improvement in the form of reduced pain/ stiffness. A total of 23 out of 58 (40%) in the study showed no improvement. Grip strength did not significantly improve in the in the treatment group. Side- effects were minimal, apart from initial exacerbation of symptoms experienced by six of the 66 patients in the trial from two to four weeks after starting the study. This increased sensitivity lasted from one to two weeks after which the individuals generally reported improvement in their symptoms. Dosage of GLM Extract dropped to 750mg per day once a positive response was seen.

Advisory: This is not intended for the diagnosis or treatment of medical complaints. It is for information purposes only.

Pollard B, Guilford WG, Ankenbauer-Perkins KL, Hedderley D. Clinical efficiency and tolerance of Biolane GLME in dogs presumptively diagnosed with degenerative joints disease. New Zealand Veterinary Journal 54 (3) 114-118, 2006

81 dogs diagnosed with DJD were treated orally daily with either GLME or placebo for 56 days in a double blind, placebo-controlled study.

In conclusion, the results of this study suggest that Biolane containing treatment used was well tolerated and had a significant beneficial effect on the clinical signs of dogs diagnosed with DJD.

Advisory: This is not intended for the diagnosis or treatment of medical complaints. It is for information purposes only.


Success Stories

Mrs. Nivedita Kamal

Retired Banker, Dwarka, New Delhi

Dr. Krishan Bir Chaudhary

President of Bharatiya Krishak Samaj

Mr. Ajay Gupta

Businessman, Faridabad, Haryana

Go to Top